Omeros hits endpoint in pivotal stem cell transplant study

A pivotal trial of Omeros’ narsoplimab in hematopoietic stem cell transplant patients has hit its primary endpoint. Omeros expects to use the data to win FDA approval, although secrecy around the design of the trial means there remains scope for skepticism about the results.